Τίτλος:
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Renal impairment (RI) is a relatively common complication of multiple myeloma, which increases in frequency as disease becomes more advanced and recovery of renal function becomes less likely as patients progress through lines of therapy. Clinical trials in the relapsed/refractory multiple myeloma (RRMM) setting have not uniformly included patients with RI or robustly reported their outcomes. Here, we review existing data among patients with RI and RRMM across drug classes (including immunomodulatory agents, proteasome inhibitors, monoclonal antibodies, antibody-drug conjugates, chimeric antigen receptor T-cell therapies, and exportin-1 inhibitor) to provide an improved understanding of available treatment options for this important population. We highlight data from pivotal clinical trials, including data relating to renal response (as defined by the International Myeloma Working Group) and discuss real-world experiences in patients with RI, where applicable. Despite substantial advances in RRMM treatment, the presence of RI remains associated with reduced overall survival. Consistent inclusion of patients with RI, and uniform reporting of their outcomes, should be encouraged in future prospective trials of treatments for RRMM. © The Author(s), 2022.
Συγγραφείς:
Dimopoulos, M.A.
Mikhael, J.
Terpos, E.
Leleu, X.
Moreau, P.
Bladé, J.
Kim, J.S.
Stockerl-Goldstein, K.
Richardson, P.G.
Περιοδικό:
Therapeutic Advances in Hematology
Εκδότης:
SAGE Publications Ltd
Λέξεις-κλειδιά:
ADP ribosyl cyclase/cyclic ADP ribose hydrolase 1; B cell maturation antigen; belantamab mafodotin; bortezomib; carfilzomib; contrast medium; daratumumab; dexamethasone; elotuzumab; exportin 1; isatuximab; ixazomib; lenalidomide; monoclonal antibody; nonsteroid antiinflammatory agent; pomalidomide; proteasome inhibitor; selinexor; thalidomide, angiogenesis; atherosclerosis; awareness; chemotherapy; chimeric antigen receptor T-cell immunotherapy; cytotoxicity; dehydration; drug efficacy; drug safety; end stage renal disease; estimated glomerular filtration rate; Fanconi anemia; fibrosis; follow up; heart failure; hemodiafiltration; hypercalcemia; kidney failure; kidney function; kidney tubule necrosis; minimal residual disease; multiple myeloma; non insulin dependent diabetes mellitus; nonhuman; overall survival; progression free survival; proximal tubule cell; renal clearance; Review; systematic review
DOI:
10.1177/20406207221088458
